Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0
|
作者：
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
机构：
[1] Hospital Ramón y Cajal,Servicio de Oncología Médica
[2] University Hospital of Wuerzburg,Department of Nuclear Medicine
[3] Central Hospital of Augsburg,Department of Nuclear Medicine
[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities
[5] Royal Marsden Hospital,Thyroid Unit
[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute
[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute
[9] Odense University Hospital,Department of Oncology, Clinical Research Unit
[10] Hospital Ramón y Cajal,Cardiology Service
[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit
[12] Autonomous University of Barcelona,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 966
页数：21
相关论文
共 50 条
  • [41] Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment
    Werner, Rudolf
    Higuchi, Takahiro
    Muegge, Dirk
    Javadi, Mehrbod
    Fassnacht, Martin
    Buck, Andreas
    Lapa, Constantin
    Kreissl, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [42] Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Del Rivero, Jaydira
    Edgerly, Maureen
    Ward, Jean
    Madan, Ravi A.
    Balasubramaniam, Sanjeeve
    Fojo, Tito
    Gramza, Ann W.
    ONCOLOGIST, 2019, 24 (01): : 16 - +
  • [43] Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome
    Pitoia, Fabian
    Bueno, Fernanda
    Schmidt, Angelica
    Lucas, Sabrina
    Cross, Graciela
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2015, 59 (04): : 343 - 346
  • [44] Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
    Wang, Linnea Hojer
    Wehland, Markus
    Wise, Petra M. M.
    Infanger, Manfred
    Grimm, Daniela
    Kreissl, Michael C. C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [45] TREATMENT WITH VANDETANIB IN A 11 YEARS OLD BOY WITH ADVANCED MEDULLARY THYROID CARCINOMA
    Papendieck, Patricia
    Vieites, Ana
    Elias, Eugenia
    Garcia Lombardi, Mercedes
    Chiesa, Ana
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 596 - 596
  • [46] Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
    Kraft, Ira L.
    Akshintala, Srivandana
    Zhu, Yuelin
    Lei, Haiyan
    Derse-Anthony, Claudia
    Dombi, Eva
    Steinberg, Seth M.
    Lodish, Maya
    Waguespack, Steven G.
    Kapustina, Oxana
    Fox, Elizabeth
    Balis, Frank M.
    Merino, Maria J.
    Meltzer, Paul S.
    Glod, John W.
    Shern, Jack F.
    Widemann, Brigitte C.
    CLINICAL CANCER RESEARCH, 2018, 24 (04) : 753 - 765
  • [47] A PHASE II STUDY OF VANDETANIB IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER
    Paz-Ares, L.
    Haddad, R.
    Krebs, A. D.
    Vasselli, J.
    Robinson, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 247 - 247
  • [48] Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer
    Modica, R.
    Pizza, G.
    Lo Calzo, F.
    De Cicco, F.
    Sciammarella, C.
    Circelli, L.
    Colao, A.
    Faggiano, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 222 - 222
  • [49] Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
    Valerio, Laura
    Bottici, Valeria
    Matrone, Antonio
    Piaggi, Paolo
    Viola, David
    Cappagli, Virginia
    Agate, Laura
    Molinaro, Eleonora
    Ciampi, Raffaele
    Tacito, Alessia
    Ramone, Teresa
    Romei, Cristina
    Elisei, Rossella
    ENDOCRINE-RELATED CANCER, 2020, 27 (02) : 97 - 110
  • [50] Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Martinez-Trufero, Javier
    Dalmau, Elsa
    Alvarez-Escala, Cristina
    Beltran, Miguel
    Duran, Manuel
    Gallegos, Isabel
    Luis Manzano, Jose
    Mesla, Ricard
    Pajares, Isabel
    Fuentes Pradera, Jose
    Grau, Juan J.
    Reig, Oscar
    Manuel Trigo, Jose
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345